News of Note—Merck, FluGen and more

In this week's news of note, Merck posted a Gardasil sales increase. (NS Newsflash/CC BY 2.0)

Here is some other vaccine news of note for the week.

> Merck's Gardasil sales grew 24% in the first quarter to $660 million. Release

> FluGen's CEO said the company will consider seeking funding from a new Gates Foundation universal flu vaccine challenge. Xconomy article

> Rational Vaccines, a company that has come under fire for unregulated vaccine testing, removed a lawsuit to federal court in Illinois. Law360 article

> Pfizer's Prevnar sales slipped 1% to $1.38 billion in the first quarter. Release (PDF)


Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.